FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy

By Reuters News

- A panel of outside experts advising the US FDA backed the safety of Grail's GRAL.O blood-based cancer detection test, Galleri, on Wednesday, though members were divided on the evidence supporting its effectiveness.

While all the 10 panel members backed Galleri's safety, support for its effectiveness was narrower, with a 6-4 vote in favor.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk